237 related articles for article (PubMed ID: 36585141)
1. Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study.
Fauria K; Minguillon C; Knezevic I; Tort-Colet N; Stankeviciute L; Hernández L; Rădoi A; Deulofeu C; Fuentes-Julián S; Turull I; Fusté D; Sánchez-Benavides G; Arenaza-Urquijo EM; Suárez-Calvet M; Holst SC; Garcés P; Mueggler T; Zetterberg H; Blennow K; Arqueros A; Iranzo Á; Domingo Gispert J; Molinuevo JL; Grau-Rivera O
BMJ Open; 2022 Dec; 12(12):e067159. PubMed ID: 36585141
[TBL] [Abstract][Full Text] [Related]
2. Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy.
Udeh-Momoh CT; Watermeyer T; Price G; de Jager Loots CA; Reglinska-Matveyev N; Ropacki M; Ketter N; Fogle M; Raghavan N; Arrighi M; Brashear R; Di J; Baker S; Giannakopoulou P; Robb C; Bassil D; Cohn M; McLellan-Young H; Crispin J; Lakey K; Lisa C; Chowdary Seemulamoodi Y; Kafetsouli D; Perera D; Car J; Majeed A; Ward H; Ritchie K; Perneczky R; Kivipelto M; Scott D; Bracoud L; Saad Z; Novak G; Ritchie CW; Middleton L
BMJ Open; 2021 Jun; 11(6):e043114. PubMed ID: 34168021
[TBL] [Abstract][Full Text] [Related]
3. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease.
Liguori C; Nuccetelli M; Izzi F; Sancesario G; Romigi A; Martorana A; Amoroso C; Bernardini S; Marciani MG; Mercuri NB; Placidi F
Neurobiol Aging; 2016 Apr; 40():120-126. PubMed ID: 26973111
[TBL] [Abstract][Full Text] [Related]
4. Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer's Disease.
Shimizu S; Takenoshita N; Inagawa Y; Tsugawa A; Hirose D; Kaneko Y; Ogawa Y; Serisawa S; Sakurai S; Hirao K; Kanetaka H; Kanbayashi T; Imanishi A; Sakurai H; Hanyu H
J Alzheimers Dis; 2020; 73(1):117-123. PubMed ID: 31744010
[TBL] [Abstract][Full Text] [Related]
5. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
6. Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease.
Koychev I; Lawson J; Chessell T; Mackay C; Gunn R; Sahakian B; Rowe JB; Thomas AJ; Rochester L; Chan D; Tom B; Malhotra P; Ballard C; Chessell I; Ritchie CW; Raymont V; Leroi I; Lengyel I; Murray M; Thomas DL; Gallacher J; Lovestone S
BMJ Open; 2019 Mar; 9(3):e024498. PubMed ID: 30904851
[TBL] [Abstract][Full Text] [Related]
7. Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol.
Gregory S; Linz N; König A; Langel K; Pullen H; Luz S; Harrison J; Ritchie CW
BMJ Open; 2022 Mar; 12(3):e052250. PubMed ID: 35292490
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process.
Gabelle A; Jaussent I; Hirtz C; Vialaret J; Navucet S; Grasselli C; Robert P; Lehmann S; Dauvilliers Y
Neurobiol Aging; 2017 May; 53():59-66. PubMed ID: 28235679
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms.
Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Bernardini S; Placidi F
J Alzheimers Dis; 2018; 66(3):993-999. PubMed ID: 30372684
[TBL] [Abstract][Full Text] [Related]
10. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
11. Remote evaluation of sleep to enhance understanding of early dementia due to Alzheimer's Disease (RESTED-AD): an observational cohort study protocol.
Blackman J; Morrison HD; Gabb V; Biswas B; Li H; Turner N; Jolly A; Trender W; Hampshire A; Whone A; Coulthard E
BMC Geriatr; 2023 Sep; 23(1):590. PubMed ID: 37742001
[TBL] [Abstract][Full Text] [Related]
12. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
13. Association between plasma exosome neurogranin and brain structure in patients with Alzheimer's disease: a protocol study.
He M; Sun L; Cao W; Yin C; Sun W; Liu P; Tan L; Xu Z; Zhao W
BMJ Open; 2020 Aug; 10(8):e036990. PubMed ID: 32801201
[TBL] [Abstract][Full Text] [Related]
14. Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation.
Liguori C; Spanetta M; Izzi F; Franchini F; Nuccetelli M; Sancesario GM; Di Santo S; Bernardini S; Mercuri NB; Placidi F
J Alzheimers Dis; 2020; 74(2):501-508. PubMed ID: 32065791
[TBL] [Abstract][Full Text] [Related]
15. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
16. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?
Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F
Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255
[TBL] [Abstract][Full Text] [Related]
17. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
18. Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease.
Olsson M; Ärlig J; Hedner J; Blennow K; Zetterberg H
Sleep; 2018 May; 41(5):. PubMed ID: 29425372
[TBL] [Abstract][Full Text] [Related]
19. Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.
Osorio RS; Ducca EL; Wohlleber ME; Tanzi EB; Gumb T; Twumasi A; Tweardy S; Lewis C; Fischer E; Koushyk V; Cuartero-Toledo M; Sheikh MO; Pirraglia E; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Schuetz S; Varga AW; Ayappa I; Rapoport DM; de Leon MJ
Sleep; 2016 Jun; 39(6):1253-60. PubMed ID: 26951396
[TBL] [Abstract][Full Text] [Related]
20. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
